ALT: Altimmune, Inc.
About
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Current Value
$7.611 Year Return
Current Value
$7.611 Year Return
Key Details
Market Cap
$531.30M
P/E Ratio
-4.8
1Y Stock Return
194.09%
1Y Revenue Growth
-81.36%
Dividend Yield
0.00%
Price to Book
4.0
Strategies that include ALT
Stock's related to ALT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RCKT | 42.81% | $1.20B | -39.83% | 0.00% |
| CLDX | 42.41% | $1.66B | -10.82% | 0.00% |
| MARA | 41.36% | $6.39B | +92.63% | 0.00% |
| PLRX | 40.91% | $778.32M | -9.55% | 0.00% |
| AXSM | 40.84% | $4.63B | +61.30% | 0.00% |
| PRTA | 40.58% | $756.01M | -56.52% | 0.00% |
| KRYS | 38.78% | $5.12B | +75.65% | 0.00% |
| CLSK | 38.59% | $3.65B | +211.70% | 0.00% |
| TGTX | 38.39% | $4.72B | +146.10% | 0.00% |
| DMRC | 38.09% | $694.39M | -2.06% | 0.00% |
| OMER | 37.52% | $349.44M | +258.93% | 0.00% |
| VKTX | 37.12% | $5.74B | +353.83% | 0.00% |
| ERIC | 37.09% | $25.52B | +67.88% | 3.20% |
| SRRK | 36.91% | $2.61B | +134.91% | 0.00% |
| KROS | 36.78% | $2.17B | +73.87% | 0.00% |
| ARWR | 36.66% | $2.31B | -34.44% | 0.00% |
| BTBT | 36.49% | $595.60M | +81.53% | 0.00% |
| PSTX | 36.30% | $269.98M | +6.13% | 0.00% |
| RIOT | 36.19% | $4.08B | +9.85% | 0.00% |
| DAWN | 36.04% | $1.36B | +13.42% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OCX | 0.01% | $42.93M | -36.09% | 0.00% |
| NGNE | 0.06% | $223.88M | +32.95% | 0.00% |
| DKL | -0.07% | $2.03B | -18.84% | 10.94% |
| LBRT | -0.07% | $2.84B | -12.59% | 1.61% |
| SSSS | 0.12% | - | - | 0.00% |
| NINE | -0.12% | $49.99M | -42.44% | 0.00% |
| STNG | -0.15% | $2.96B | +0.87% | 2.75% |
| MNST | -0.22% | $52.25B | -1.95% | 0.00% |
| AMPY | -0.22% | $260.89M | +7.01% | 0.00% |
| KNDI | 0.24% | $96.53M | -60.11% | 0.00% |
| OCFT | 0.31% | $80.95M | -30.38% | 0.00% |
| RSG | 0.32% | $66.05B | +31.79% | 1.04% |
| FANG | -0.33% | $52.59B | +18.15% | 2.79% |
| DIS | 0.36% | $203.59B | +19.03% | 0.40% |
| LMT | -0.37% | $126.40B | +18.99% | 2.36% |
| DLNG | -0.40% | $161.93M | +73.23% | 0.00% |
| AOUT | -0.41% | $118.33M | +9.76% | 0.00% |
| BRY | 0.41% | $323.14M | -39.04% | 10.40% |
| CAH | 0.42% | $28.64B | +12.14% | 1.70% |
| HPE | 0.45% | $27.96B | +37.84% | 2.42% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CYD | -14.51% | $364.46M | -2.94% | 4.26% |
| TCTM | -13.33% | $8.10M | -42.99% | 0.00% |
| STG | -12.53% | $35.67M | +7.92% | 0.00% |
| CI | -12.35% | $89.70B | +12.57% | 1.68% |
| CQP | -12.28% | $25.90B | -6.77% | 5.96% |
| TEM | -11.02% | $8.50B | 0.00% | 0.00% |
| ARLP | -11.00% | $3.54B | +26.77% | 10.11% |
| RDDT | -10.34% | $24.08B | +303.41% | 0.00% |
| PRT | -9.96% | $48.72M | -16.56% | 10.33% |
| BF.B | -9.85% | $19.01B | -31.35% | 2.18% |
| MCK | -9.71% | $78.15B | +35.51% | 0.42% |
| CBOE | -9.39% | $21.46B | +15.84% | 1.11% |
| CVE | -9.32% | $29.32B | -10.19% | 2.95% |
| SU | -9.05% | $52.05B | +23.58% | 3.92% |
| IMRN | -8.89% | $10.31M | -5.04% | 0.00% |
| DK | -8.46% | $1.14B | -34.04% | 5.64% |
| CANG | -8.33% | $253.50M | +212.50% | 0.00% |
| SCKT | -8.20% | $10.88M | +15.32% | 0.00% |
| NGL | -8.07% | $572.94M | +5.60% | 0.00% |
| NHTC | -7.98% | $61.83M | +0.19% | 14.81% |
ETF's related to ALT
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -27.81% | $388.04M | 1.43% |
| VIXY | -18.65% | $195.31M | 0.85% |
| USCI | -16.39% | $185.47M | 1.07% |
| DBO | -14.72% | $217.57M | 0.77% |
| DBE | -13.34% | $50.13M | 0.77% |
| COMT | -12.04% | $829.06M | 0.48% |
| UUP | -11.96% | $309.25M | 0.77% |
| GSG | -11.56% | $914.42M | 0.75% |
| FTGC | -11.14% | $2.17B | 1.02% |
| USDU | -10.56% | $201.97M | 0.5% |
| PDBC | -10.33% | $4.40B | 0.59% |
| DBA | -10.21% | $755.88M | 0.93% |
| KMLM | -10.20% | $353.87M | 0.9% |
| CTA | -9.89% | $350.27M | 0.78% |
| TPMN | -9.82% | $40.60M | 0.65% |
| EQLS | -9.55% | $76.08M | 1% |
| MINT | -9.25% | $11.62B | 0.35% |
| SGOV | -6.41% | $27.53B | 0.09% |
| KCCA | -6.21% | $220.51M | 0.87% |
| BCD | -5.92% | $245.02M | 0.3% |
News
Finnhub
GAITHERSBURG - Altimmune, Inc. , a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver...
Yahoo
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (G
Yahoo
Altimmune ( NASDAQ:ALT ) Third Quarter 2024 Results Key Financial Results Net loss: US$22.8m (loss widened by 11% from...
SeekingAlpha
Altimmuneâs Pemvidutide aims for Phase 2b MASH study results in 2025. See why ALT stock could surge with the global obesity market expected to hit $200 billion.
SeekingAlpha
Altimmuneâs lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a strong buy with a promising future.
Yahoo
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, Novembe
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.